Theratechnologies Inc.: Securities Class Action Update

(firmenpresse) - MONTREAL, CANADA -- (Marketwired) -- 07/17/13 -- Theratechnologies Inc. (TSX: TH) announced today that the Court of Appeal of Quebec has dismissed Theratechnologies' motion to dismiss the authorization to institute a class action and an action based on the secondary market liability provisions of the Securities Act (Quebec) against Theratechnologies, a former Chair of the Board of Directors and a former president and chief executive officer.

The Court of Appeal decision confirms a decision issued by the Superior Court of Quebec on February 24, 2012 which granted an authorization to the representative of persons who were shareholders at May 21, 2010 and who sold their common shares of the Company on May 25 or 26, 2010 to institute a class action against the Company, a former Chair of the Board of Directors and a former president and chief executive officer.

Theratechnologies intends to contest any class action that the shareholders' representative could institute as a result of this decision since we consider that it would be without merit.

About Theratechnologies

Theratechnologies (TSX: TH) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on the SEC's website at .



Contacts:
Denis Boucher
NATIONAL Public Relations
514-843-2393

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 17.07.2013 - 22:00 Uhr
Sprache: Deutsch
News-ID 279458
Anzahl Zeichen: 0

contact information:
Town:

MONTREAL, CANADA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 245 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Theratechnologies Inc.: Securities Class Action Update"
steht unter der journalistisch-redaktionellen Verantwortung von

Theratechnologies Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review ...

MONTREAL, QUEBEC -- (Marketwired) -- 11/13/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced that it was notified today by its partner, TaiMed Biologics, Inc. ("TaiMed"), that the U.S. Food and Drug Administration (&quo ...

Theratechnologies Announces Financial Results for Third Quarter of 2017 ...

MONTREAL, QUEBEC -- (Marketwired) -- 10/05/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2017.Third quarter 2017 financial highlights"With three quarters ...

Theratechnologies Announces 48-Week Efficacy and Safety Results for Ibalizumab P ...

MONTREAL, QUEBEC -- (Marketwired) -- 10/04/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced 48-week efficacy and safety results for ibalizumab in patients infected with multidrug resistant HIV-1 who completed the 24-week P ...

Alle Meldungen von Theratechnologies Inc.